Translating future value into current shareholder liquidity requires a balanced approach and diverse skill set. Especially for early-stage or pre-revenue life sciences companies, this problem is compounded. Our experienced scientific and financial teams combine to communicate your company’s unique value proposition and future market potential. With an array of transactional structures to select from, our team explores the various avenues available to facilitation value realization.
Our professionals are well-versed in structures ranging from outright M&A to build-to-buy option agreements, sales-based structured transactions to private-equity platform investments. Our deep network of senior executives spanning public, private, strategic and financial buyers facilitate quick and thoughtful market feedback instrumental towards crafting a market-aligned transaction strategy.
Would you like to learn more about working with Outcome Capital or discuss your specific needs?